

11-29-01

A

Attorney's Docket No. 8707.2133
138-Discrimination F

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Commissioner for Patents
2900 Crystal Drive
Arlington, VA 22202-3513

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): Christine HENRY and Marcel LIMOUSIN

For (title): DISCRIMINATION OF ATRIAL FIBRILLATIONS FOR AN ACTIVE
IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR A
DEFIBRILLATOR/CARDIOVERTOR

1. Type of Application

This new application is for a(n)

- ☒ Original (nonprovisional)
☐ Design
☐ Plant
☐ Divisional.
☐ Continuation.
☐ Continuation-in-part (C-I-P)

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal
and the documents referred to as enclosed therein are
being deposited with the United States Postal Service

on this date November 27, 2001, in an envelope as
"Express Mail Post Office to Addressee" Mailing
Label Number EL 228 657 614US, addressed to the:
Commissioner for Patents, 2900 Crystal Drive,
Arlington, VA 22202-3513.

Lorraine Glorig
(Lorraine Glorig)

2. Benefit of Prior U.S. Application(s) (35 U.S.C. 119(e), 120, or 121)

- ☐ This new application being transmitted claims the benefit of prior U.S. application(s). Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

2. Papers Enclosed That Are Required for Filing Date under 37 C.F.R. 1.53(b) (Regular) or 37 C.F.R. 1.153 (Design) Application

<u>11</u>	Pages of Specification
<u>3</u>	Pages of claims
<u>1</u>	Pages of Abstract
<u>0</u>	Sheets of drawings

- ☐ formal
- ☐ informal
- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWINGS." 37 C.F.R. 1.84(b).

3. Additional papers enclosed

- ☐ Preliminary Amendment
- ☒ Information Disclosure Statement (37 C.F.R. 1.98)
- ☒ Form PTO-1449 (PTO/SB/08A and 08B)
- ☐ Citations
- ☐ Declaration of Biological Deposit
- ☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☐ Special Comments

☐ Other-

4. Declaration or oath

☒ Enclosed is an unexecuted original declaration/power of attorney

Executed by

☐ inventor(s).

☐ legal representative of inventor(s).
37 C.F.R. 1.42 or 1.43.

☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.

☐ This is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. *See item 13 below for fee.*

☐ Not Enclosed.

☐ Application is made by a person authorized under 37 CFR 1.41(c) on behalf of *all* the above named inventor(s).

(The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently).

☐ Showing that the filing is authorized.
(not required unless called into question. 37 CFR 1.41(d))

5. Inventorship Statement

The inventorship for all the claims in this application are:

☐ The same.

or

☐ Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made.

☐ is submitted.

☐ will be submitted.

6. Language

☒ English

☐ Non-English

☐ The attached translation is a verified translation. 37 C.F.R. 1.52(d).

7. Assignment

☒ An assignment of the invention

☐ is attached. A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☐ FORM PTO 1595 is also attached.

☒ will follow.

☐ The prior application is assigned to _____, recorded at reel/frame numbers _____.

8. Certified Copy

Certified copy(ies) of application(s)

France	00-15293	November 27, 2000
Country	Appln. no.	Filed
Country	Appln. no.	Filed
Country	Appln. no.	Filed

from which priority is claimed

☐ is (are) attached.

☒ will follow.

9. Fee Calculation (37 C.F.R. 1.16)

A. ☒ Regular application

CLAIMS AS FILED				
Number filed		Number Extra	Rate	Basic Fee 37 C.F.R. 1.16(a) \$740.00
Total Claims (37 CFR 1.16(c))	9 - 20 =	0	x \$ 18.00 =	
Independent Claims (37 CFR 1.16(b))	1 - 3 =	1	x \$ 80.00 =	
Multiple dependent claim(s), if any (37 CFR 1.16(d))			+ \$ 270.00 =	\$

- ☐ Amendment cancelling extra claims is enclosed.
- ☐ Amendment deleting multiple-dependencies is enclosed.
- ☐ Fee for extra claims is not being paid at this time.

Filing Fee Calculation \$740.00

B. ☐ Design application
(\$330.00 - 37 CFR 1.16(f))

Filing Fee Calculation \$

C. ☐ Plant application
(\$530.00 - 37 CFR 1.16(g))

Filing Fee Calculation \$ 740.00

10. Small Entity Statement(s)

☐ Verified Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 ☐ is (are) attached . ☐ will follow.

☐ Status as a small entity was claimed in prior application

/ , filed on , from which benefit
is being claimed for this application under:

35 U.S.C. ☐ 119(e),

☐ 120,

☐ 121,

☐ 365(c),

and which status as a small entity is still proper and desired.

☐ A copy of the verified statement in the prior application is included.

Filing Fee Calculation (50% if A, B or C above) \$ _____

11. Request for International -- Type Search (37 C.F.R. 1.104(d))

(complete, if applicable)

☐ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

12. Fee Payment Being Made at This Time

☒ Not Enclosed

☒ No filing fee is to be paid at this time.
(This and the surcharge required by 37 C.F.R. 1.16(e) can
be paid subsequently.)

☐ Enclosed

☐ Basic filing fee \$ _____

☐ Recording assignment
(\$40.00; 37 C.F.R. 1.21(h))
(See attached "COVER SHEET FOR ASSIGNMENT
ACCOMPANYING NEW APPLICATION".) \$ _____

☐ Petition fee for filing by other than all the inventors or
person on behalf of the inventor where inventor refused to
sign or cannot be reached
(\$130.00; 37 C.F.R. 1.52(d) and 1.17(k)) \$ _____

☐ For processing an application with a specification in a non-
English language
(\$130.00; 37 C.F.R. 1.52(d) and 1.17(k)) \$ _____

☐ Processing an retention fee
(\$130.00; 37 C.F.R. 1.53(d) and 1.21(l)) \$ _____

☐ Fee for international-type search report
(\$40.00; 37 C.F.R. 1.21(e)) \$ _____

Total fees enclosed \$ _____

13. Method of Payment of Fees

☐ Check in the amount of

☐ Charge Account No. _____ in the amount of \$

☒ A duplicate of this transmittal is attached.

14. Authorization to Charge Additional Fees

- ☒ The Commissioner is hereby authorized to charge the following additional fees required by this paper and during the entire pendency of this application to Account No. 15-0665.
- ☒ 37 C.F.R. 1.16(a), (f) or (g) (filing fees)
- ☒ 37 C.F.R. 1.16(b), (c) and (d) (presentation of extra claims)
- ☒ 37 C.F.R. 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- ☒ 37 C.F.R. 1.17 (application processing fees)
- ☐ 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

15. Instructions as to Overpayment

- ☒ Credit Account No. 15-0665
- ☐ Refund



SIGNATURE OF ATTORNEY

Reg. No. 31,110

(type or print name of attorney)

Tel. No. (212) 506-5000

Robert M. Isackson
ORRICK, HERRINGTON & SUTCLIFFE LLP
666 Fifth Avenue
New York, New York 10103-0001

☐ **Incorporation by reference of added pages**

- ☐ Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added _____

- ☐ Plus Added Pages for Papers Referred to in Item 4 Above

Number of pages added _____

- ☐ Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added _____

☒ **Statement Where No Further Pages Added**

- ☒ This transmittal ends with this page.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100